Sekihara H
J Steroid Biochem. 1983 Jul;19(1A):353-8.
The hypertensinogenic effects of 19-hydroxyandrostenedione (19-OH-A-dione), which we reported as an amplifier of the action of aldosterone on the basis of the results obtained in bioassays using adrenalectomized rats, were evaluated in intact rats with both adrenals and kidneys. The administration of 19-OH-A-dione to the rats caused sodium retention and the 19-OH-A-dione treated rats developed high blood pressure, suppressed plasma renin activity and low plasma aldosterone, corticosterone and deoxycorticosterone concentrations. The hypertensinogenic potency of 19-OH-A-dione was incomparably higher than that of DOCA. The results indicate that 19-OH-A-dione is a potent hypertensinogenic steroid and causes the hypertensive state similar to mineralocorticoid excess. The evaluation of 19-OH-A-dione concentrations in human plasma revealed that 19-OH-A-dione is present in human peripheral circulation. It appears to be secreted by the adrenal cortex under the control of ACTH and the renin-angiotensin system. Plasma 19-OH-A-dione concentrations in patients with normal renin essential hypertension and low renin essential hypertension are higher than those in control subjects. 19-OH-A-dione is a newly recognised hypertensinogenic steroid in man.
19-羟雄烯二酮（19-OH-A-二酮）的致高血压作用，我们曾根据对肾上腺切除大鼠进行生物测定所得结果，将其报告为醛固酮作用的增强剂，现对具有双侧肾上腺和肾脏的完整大鼠进行了评估。给大鼠施用19-OH-A-二酮会导致钠潴留，且经19-OH-A-二酮处理的大鼠出现高血压、血浆肾素活性受到抑制以及血浆醛固酮、皮质酮和脱氧皮质酮浓度降低。19-OH-A-二酮的致高血压效力远高于去氧皮质酮醋酸酯（DOCA）。结果表明，19-OH-A-二酮是一种强效的致高血压类固醇，可导致类似于盐皮质激素过多的高血压状态。对人血浆中19-OH-A-二酮浓度的评估显示，19-OH-A-二酮存在于人体外周循环中。它似乎是在促肾上腺皮质激素（ACTH）和肾素-血管紧张素系统的控制下由肾上腺皮质分泌的。正常肾素型原发性高血压患者和低肾素型原发性高血压患者的血浆19-OH-A-二酮浓度高于对照受试者。19-OH-A-二酮是人类新发现的一种致高血压类固醇。
